Science Award - February 23, 2022
Danish virologist receives the Hagedorn Prize
Jens Bukh has contributed to giving thousands of people a better and longer life through his research within hepatitis C. Jens Bukh heads the Copenhagen Hepatitis C Program at the Department of Infectious Diseases at Copenhagen University Hospital, Amager-Hvidovre and the Department of Immunology and Microbiology at the University of Copenhagen. Hepatitis C can be […]
Clinical Trials - January 17, 2014
Interim results from a phase II all-oral combination study of Simeprevir and Samatasvir
Medivir announces that Idenix Pharmaceuticals today released interim data from the ongoing phase II HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor, and simeprevir , a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, and ribavirin. The combination regimen of the […]
Clinical Trials - October 25, 2013
Medivir announce data from phase III studies
The Swedish company has announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. “Based on these encouraging data with the high cure rates seen in […]
